Navigation Links
Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
Date:2/26/2009

any intends to submit an abstract to the European Association for the Study of the Liver (EASL) to present antiviral and safety data from all three dose levels at the EASL Annual Meeting in late April.
  • 14-day Healthy Volunteer Study. In order to extend the pharmacokinetic and safety profile of ANA598, Anadys has initiated a 14-day study of ANA598 in healthy volunteers, in which subjects will receive ANA598 at dose levels of 400 mg, 800 mg, 1200 mg once-daily (QD) and 600 mg twice-daily. Enrollment of the 400 mg cohort is complete, and Anadys expects to receive the data from the full study in the second quarter of 2009.
  • Safety and PK Results for ANA598 in Healthy Volunteers. Single-dose safety and pharmacokinetic results from a Phase I study of ANA598 in healthy volunteers at doses ranging from 400 to 3000 mg were reported at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in November 2008. ANA598 was well tolerated at all doses and there were no serious adverse events or withdrawals from the study. Preclinical results for ANA598 were also reported at AASLD, including data demonstrating that the in vitro virology profile of ANA598 strongly supports clinical exploration of ANA598 in combination with interferon-alpha and with direct antivirals now in development, including protease inhibitors and nucleoside polymerase inhibitors.
  • Long-Term Chronic Toxicology Studies of ANA598. In September 2008, Anadys initiated long-term, chronic toxicology studies of ANA598 comprised of a 6-month study in rats and a 9-month study in monkeys, as well as embedded 3-month arms in both species. Anadys expects to receive full results from the 3-month arms by the end of the first quarter of 2009.
  • ANA773

    ANA773 is an oral prodrug of a small molecule inducer of endogenous interferons that acts via the to
    '/>"/>

    SOURCE Anadys Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine news :

    1. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
    2. Anadys Pharmaceuticals to Present at Bio Investor Forum
    3. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
    4. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
    5. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
    6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
    7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
    8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
    9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
    10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
    11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
    (Date:10/22/2014)... 22, 2014 Although there are only 24 hours ... many people who have trouble finding time within their busy schedules ... for long periods of time to get in shape. Here are ... on the go. , Change Up Your Commute , Consider ... to add some exercise into your daily routine. If you must ...
    (Date:10/22/2014)... 22, 2014 Richard Carlson, Managing Partner ... leader with over 25 years experience. Mr. Carlson ... the areas related to EDI, B2B Commerce, RFID and ... Editorial Advisory Board member for Pharmaceutical Commerce Magazine and ... Fin Group is a management and technology consulting firm ...
    (Date:10/22/2014)... Reinberg HealthDay Reporter , TUESDAY, ... weight and length may be showing a genetic propensity for ... certain genes have been linked to increased body fat, but ... and lean muscle, the researchers said. At 1 year, ... ages 2 and 3, however, these genes were linked to ...
    (Date:10/22/2014)... 2014 (HealthDay News) -- Two sisters in high school ... Ilina and Medha Krishen use electronic stethoscopes, which ... trouble in breathing patterns or heartbeats. Ilina, a ... wanted to find a way to detect early lung ... an electronic stethoscope, Ilina recorded one breath cycle each ...
    Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:HealthGuideMD Presents Ways to Improve Your Exercise and Fitness 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2
    ... Feb. 10 SilverCensus.com Inc. ( http://www.silvercensus.com ), ... healthcare professionals, announced today its expansion to a ... a Foundation that aims to revolutionize the way ... are a comprehensive senior living and senior healthcare ...
    ... Myeloma and Bone Cancer Research (IMBCR) have uncovered a ... within tumors.LOS ANGELES, Feb. 10 IMBCR researchers uncovered ... their own blood supply. Recent studies have shown that ... now show that PTN produced by tumor cells in ...
    ... AVC-Intra encoding, 64-bit support, seamless integration and improved quality ... MainConcept GmbH, a wholly-owned subsidiary of DivX, Inc. ... world,s leading providers of video/audio codecs and software development ... today announced the release of Codec SDK 8.0 with ...
    ... Technique Breast-Specific Gamma Imaging (BSGI) Resulting in Record ... Technologies, Inc., a leader in molecular breast imaging, ... the strongest fourth quarter in the company,s history. ... sales from 2007 to 2008 as molecular breast ...
    ... Feb. 10 Arete Therapeutics Inc. today,announced the initiation ... orally-,administered soluble epoxide hydrolase (s-EH) inhibitor being developed for,the ... involved in the metabolism,of arachidonic acid, a key signaling ... "Our AR9281 Phase II clinical trial ...
    ... Feb. 10 - Zeus, Inc. announces new product name changes that ... unaltered in composition and processing. They remain the same quality products ... , New brand names are as follows: , ... New trademarked product Aeos (TM), formerly known as ...
    Cached Medicine News:Health News:SilverCensus.com Launches National Website for Caregivers, Senior Citizens, Healthcare Professionals 2Health News:Researchers Identify Novel Mechanism That Make Cancer Tumors Grow 2Health News:MainConcept Releases New Codec SDK 8.0 2Health News:MainConcept Releases New Codec SDK 8.0 3Health News:MainConcept Releases New Codec SDK 8.0 4Health News:Dilon Technologies Leads Molecular Breast Imaging Expansion 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 2Health News:Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes 3Health News:Zeus Announces Product Name Changes 2
    (Date:10/22/2014)... CITY, Calif. , Oct. 22, 2014 /PRNewswire/ ... today announced that results from the  IAP310 study ... Pain Medicine (RAPM), a peer-reviewed journal with ... Phase 3 trial evaluating the safety and efficacy ... sublingual tablet system (SSTS), for the treatment of ...
    (Date:10/22/2014)... Oct. 22, 2014  Regulus Therapeutics Inc. ... company leading the discovery and development of ... it has demonstrated human proof-of-concept with a ... evaluating RG-101, a wholly-owned, GalNac-conjugated anti-miR targeting ... C virus infection ("HCV").  Interim results from ...
    (Date:10/20/2014)... , Oct. 20, 2014  PneumRx, Inc. ( ... pulmonology, today announced completion of enrollment in their RENEW ... Clinical Study is the FDA-approved IDE pivotal trial for ... emphysema. It was anticipated that the study, ... 2013, would take until the end of 2014 to ...
    Breaking Medicine Technology:AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8PneumRx Completes RENEW Pivotal Trial Enrollment 2PneumRx Completes RENEW Pivotal Trial Enrollment 3
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    Medicine Products: